@article{MTMT:36926625,
	title = {Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy},
	url = {https://m2.mtmt.hu/api/publication/36926625},
	author = {Péterfia, Csaba and Komlósi, Zsolt I. and Pós, Zoltán and Lupsa, Nikolett and Fekete, Nóra and Böröcz, Katalin and Dergez, Tímea and Leibinger, Evelin A. and Benedek, Noémi and Vojcek, Ágnes and Horváth, Bence and Vertike, Vita and Csanádi, Krisztina and Hauser, Péter and Tiszlavicz, Lilla Györgyi and Erdélyi, Dániel and Brückner, Edit and Szabó, Sándor and Beniczky, Nikolett Jusztina and Berki, Timea and Ottóffy, Gábor},
	doi = {10.3389/fimmu.2026.1728845},
	journal-iso = {FRONT IMMUNOL},
	journal = {FRONTIERS IN IMMUNOLOGY},
	volume = {17},
	unique-id = {36926625},
	issn = {1664-3224},
	year = {2026},
	eissn = {1664-3224},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975; Erdélyi, Dániel/0000-0001-5544-9209; Brückner, Edit/0000-0002-2140-3357}
}

@misc{MTMT:35774211,
	title = {EWING},
	url = {https://m2.mtmt.hu/api/publication/35774211},
	author = {Hauser, Péter},
	unique-id = {35774211},
	year = {2025},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:35798493,
	title = {Molecular profiling reveals novel gene fusions and genetic markers for refined patient stratification in pediatric acute lymphoblastic leukemia},
	url = {https://m2.mtmt.hu/api/publication/35798493},
	author = {Péterffy, Borbála and Krizsán, Szilvia and Egyed, Bálint and Bedics, Gábor and Benard-Slagter, Anne and Palit, Sander and Erdélyi, Dániel and Müller, Judit and Nagy, Tibor and Hegyi, Lajos and Bekő, Anna and Kenéz, Lili Anna and Jakab, Zsuzsanna and Péter, György and Zombori, Marianna and Csanádi, Krisztina and Ottóffy, Gábor and Csernus, Katalin and Vojcek, Ágnes and Tiszlavicz, Lilla Györgyi and Gábor, Krisztina and Kelemen, Ágnes and Hauser, Péter and Kállay, Krisztián Miklós and Kertész, Gabriella and Gaál, Zsuzsanna and Szegedi, István and Barna, Gábor and Márk, Ágnes and Haltrich, Irén and Hevessy Zsuzsanna, Dóra and Ujfalusi, Anikó and Kajtár, Béla and Timár, Botond and Kiss, Csongor and Kriván, Gergely and Matolcsy, András and Savola, Suvi and Kovács, Gábor and Bödör, Csaba and Alpár, Donát},
	doi = {10.1016/j.modpat.2025.100741},
	journal-iso = {MODERN PATHOL},
	journal = {MODERN PATHOLOGY},
	volume = {38},
	unique-id = {35798493},
	issn = {0893-3952},
	abstract = {Risk-adapted treatment protocols conferred remarkable improvement in the survival rates of pediatric acute lymphoblastic leukemia/lymphoma (ALL/LBL). Nevertheless, clinical management is still challenging in certain molecular subgroups and in the presence of alterations associated with an increased rate of relapse. In this study, disease-relevant genomic and transcriptomic profiles were established in a prospective, multicenter, real-world cohort involving 192 children diagnosed with ALL/LBL. Gene fusions were detected in 34.9% of B-ALL and 46.4% of T-ALL patients, with novel chimeric genes involving JAK2, KMT2A, PAX5, RUNX1 and NOTCH1, and with KMT2A-rearranged patients displaying the worst 3-year event-free survival (p=0.019). Non-synonymous mutations were uncovered in 74.9% of the analyzed patients, and a pairwise scrutiny of genetic lesions revealed recurrent clonal selection mechanisms commonly converging on the same pathway (e.g. Ras, JAK/STAT and Notch) in individual patients. Investigation of matched diagnostic and relapse samples unraveled complex subclonal variegation, and mutations affecting the NT5C2, TP53, CDKN2A, and PIK3R1 genes, emerging at the time of relapse. TP53 and CREBBP mutations, even as subclonal aberrations, were associated with shorter 3-year event-free survival among all patients with B-ALL (TP53 mutant vs wild-type: p=0.008, CREBBP mutant vs wild-type: p=0.010); and notably, B-ALL patients showing no measurable residual disease on day 33 could be further stratified based on TP53 mutational status (p<0.001). Our in-depth molecular characterization performed across all risk groups identified novel opportunities for molecularly targeted therapy in 55.9% of high-risk and in 31.6% of standard/intermediate-risk patients.},
	year = {2025},
	eissn = {1530-0285},
	orcid-numbers = {Krizsán, Szilvia/0000-0002-1782-9275; Egyed, Bálint/0000-0001-8783-9025; Bedics, Gábor/0000-0003-4628-2384; Erdélyi, Dániel/0000-0001-5544-9209; Müller, Judit/0000-0002-0488-7759; Nagy, Tibor/0000-0002-4451-0796; Jakab, Zsuzsanna/0000-0002-5410-1187; Csanádi, Krisztina/0009-0001-6277-0137; Gábor, Krisztina/0000-0002-2473-1356; Hauser, Péter/0000-0002-8307-8975; Kállay, Krisztián Miklós/0000-0002-4328-9612; Barna, Gábor/0000-0003-1960-5061; Haltrich, Irén/0000-0003-0094-5285; Kajtár, Béla/0000-0001-5551-3709; Timár, Botond/0000-0001-6210-8154; Matolcsy, András/0000-0002-5382-2150; Kovács, Gábor/0000-0001-9924-1645; Bödör, Csaba/0000-0002-0729-692X}
}

@article{MTMT:36062788,
	title = {Postoperative word-finding difficulties in children with posterior fossa tumours. a crosslinguistic European cohort study.},
	url = {https://m2.mtmt.hu/api/publication/36062788},
	author = {Persson, K and Grønbæk, J and Tiberg, I and Fyrberg, Å and Castor, C and Andreozzi, B and Frič, R and Hauser, Péter and Kiudeliene, R and Mallucci, C and Mathiasen, R and Nyman, P and Pizer, B and Sehested, A and Boeg Thomsen, D},
	doi = {10.1007/s00381-025-06787-4},
	journal-iso = {CHILD NERV SYST},
	journal = {CHILDS NERVOUS SYSTEM},
	volume = {41},
	unique-id = {36062788},
	issn = {0256-7040},
	abstract = {Posterior fossa tumour (PFT) surgery carries a risk of mutism or severely reduced speech. As for higher-cognitive language functions, word-finding difficulties have been reported, but no study has compared pre- and postoperative word-finding speeds to identify impairment caused by surgery. The current study investigated changes in word-finding ability associated with PFT surgery and examined factors affecting postoperative ability.We included 184 children aged 5:0-17:9 years undergoing PFT surgery and assessed word-finding ability before and after surgery using a speeded picture-naming test. We compared postoperative word-finding performance with both preoperative performance and age-specific norms and examined factors affecting word-finding ability.We found no significant difference between pre- and postoperative performance, reflecting that some children exhibited better word-finding ability after surgery, others poorer. After surgery, 95% of the children performed two standard deviations above (slower than) age-specific norms. Tumour location in the fourth ventricle negatively affected postoperative word-finding ability (B = -4.09, p < 0.05).For some children, PFT surgery leads to postoperative word-finding difficulties, emphasizing the importance of postoperative language assessments and interventions. Fourth-ventricle tumour location emerged as a risk factor for poorer postoperative word-finding ability, likely reflecting surgical damage to the dentato-thalamo-cortical pathway (DTCP).},
	keywords = {LANGUAGE IMPAIRMENT; Child Language; word-finding difficulties; Posterior fossa tumour; cerebellar mutism syndrome; Postoperative speech impairment (POSI)},
	year = {2025},
	eissn = {1433-0350},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:36076974,
	title = {Tumour volume as a predictor of postoperative speech impairment in children undergoing resection of posterior fossa tumours. a prospective, multicentre study.},
	url = {https://m2.mtmt.hu/api/publication/36076974},
	author = {Laustsen, Aske Foldbjerg and Avula, Shivaram and Grønbæk, Jonathan and Pizer, Barry and Nyman, Per and Nilsson, Pelle and Frič, Radek and Hjort, Magnus Aasved and Beneš, Vladimír and Hauser, Péter and Pálmafy, Beatrix and Rutkauskiene, Giedre and Wilhelmy, Florian and Brandsma, Rick and Sehested, Astrid and Mathiasen, René and Juhler, Marianne},
	doi = {10.1007/s00701-025-06459-x},
	journal-iso = {ACTA NEUROCHIR},
	journal = {ACTA NEUROCHIRURGICA},
	volume = {167},
	unique-id = {36076974},
	issn = {0001-6268},
	abstract = {Cerebellar Mutism Syndrome (CMS) is a neurological complication of posterior fossa (PF) tumour surgery in children, and postoperative speech impairment (POSI) is the cardinal symptom of CMS. The role of tumour volume on the risk of POSI remains unexplored. This study investigates the association between tumour volume and the risk of POSI.We included 360 patients from the European CMS study with available preoperative T1-weighted contrast-enhanced brain MRI. Speech status was assessed within two weeks postoperatively and categorised into three levels: habitual speech, severely reduced speech, and mutism. Tumour volumes were calculated using the BrainLab Elements SmartBrush™, a semi-automated segmentation tool. We used proportional odds models to estimate the odds ratio (OR) with adjustments for tumour location, pathology, and age. Based on the primary analysis, a risk stratification model for medulloblastoma patients was constructed, and the optimal volume cut-off was determined with Youden's Index.We found no effect of the overall tumour volume on the risk of POSI. This result did not change when adjusted for tumour location, pathology, and age. We found an association between tumour volume of medulloblastoma and the risk of POSI (unadjusted OR of 1.04 per increase in cm3 (95% CI 1.01;1.07, p = 0.01)), which did not change when adjusting for tumour location and age. The risk stratification cut-off for the tumour volume of medulloblastoma was calculated to be 16,5 cm3. Patients with medulloblastoma and preoperative tumour volumes below 16,5 cm3 had an absolute risk of 13% for POSI (low-risk group), whereas patients with preoperative tumour volumes above 16,5 cm3 had an absolute risk of 50% for POSI (high-risk group).Our data showed an association between preoperative tumour volume and the risk of POSI in children with medulloblastoma, while no association was found for the volume of other tumour types. We suggest a straightforward cut-off risk model for assessing the risk of POSI in children with medulloblastoma based on preoperative tumour volume. This approach can aid clinicians in informing patients and parents about the complications related to CMS following PF tumour surgery in children.ID NCT02300766 (October 2014).},
	keywords = {VOLUMETRY; Paediatrics; CMS; PFS; Posterior fossa tumour; Postoperative speech impairment},
	year = {2025},
	eissn = {0942-0940},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:36263026,
	title = {Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairment},
	url = {https://m2.mtmt.hu/api/publication/36263026},
	author = {Sarup, R. and Laustsen, A.F. and Sørensen, M.K. and Mallucci, C. and Pizer, B. and Aquilina, K. and Molinari, E. and Hjort, M.A. and Frič, R. and Nyman, P. and Sabel, M. and Nilsson, P. and Matukevičius, A. and Hauser, Péter and Mudra, Katalin and Carai, A. and Zipfel, J. and Hoving, E. and van, Baarsen K. and IIIrd, V.B. and Peyrl, A. and Nysom, K. and Sehested, A.M. and Schmiegelow, K. and Juhler, M. and Grønbæk, J.K. and Mathiesen, R.},
	doi = {10.1007/s00381-025-06850-0},
	journal-iso = {CHILD NERV SYST},
	journal = {CHILDS NERVOUS SYSTEM},
	volume = {41},
	unique-id = {36263026},
	issn = {0256-7040},
	year = {2025},
	eissn = {1433-0350},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:36355531,
	title = {Postoperative speech impairment and cranial nerve deficits in children undergoing posterior fossa tumor surgery with intraoperative MRI - a prospective multinational study},
	url = {https://m2.mtmt.hu/api/publication/36355531},
	author = {Laustsen, Aske Foldbjerg and Gronbaek, Jonathan Kjaer and Fric, Radek and Avula, Shivaram and Mallucci, Conor and Nilsson, Pelle and Nyman, Per and Hauser, Péter and Mudra, Katalin and Kiudeliene, Rosita and Rocka, Saulius and Hjort, Magnus Aasved and Brandsma, Rick and Hoving, Eelco and Carai, Andrea and Benes, Vladimir and Taborska, Jana and Dorfer, Christian and Jacobs, Sandra and Pavon-Mengual, Miriam and Skjoth-Rasmussen, Jane and Schmiegelow, Kjeld and Sehested, Astrid and Mathiasen, Rene and Juhler, Marianne},
	doi = {10.1007/s00701-025-06669-3},
	journal-iso = {ACTA NEUROCHIR},
	journal = {ACTA NEUROCHIRURGICA},
	volume = {167},
	unique-id = {36355531},
	issn = {0001-6268},
	abstract = {Background Postoperative speech impairment (POSI) and cranial nerve deficits (CND) are common complications of pediatric posterior fossa (PF) tumor surgery. Intraoperative MRI (ioMRI) has proven a useful tool in achieving gross total resection. The risk of POSI and CND with ioMRI remains unclear, making it the primary scope of this study. Additionally, we assessed whether POSI was associated with CND. Methods We prospectively included pediatric patients undergoing PF tumor surgery in 36 centers across 15 European countries. Neurological status and speech were assessed preoperatively and 1-4 weeks postoperatively. Surgical details, including tumor location and use of ioMRI, were recorded within 72 h of surgery. Postoperative CND were categorized as 0, 1, 2, or >= 3 nerves affected; POSI as habitual, reduced speech, or mutism. Proportional odds models estimated odds ratios (OR) for 1) POSI with stepwise adjustment for tumor location and age, and 2) CND with adjustment for preoperative CND and tumor location. Subgroup analyses assessed systematic differences, missing data, center-level effects, and histology adjustment. ResultsOf 790 primary PF tumor surgeries, 141 (18%) involved ioMRI. POSI occurred in 183/790 (23%) and postoperative CND in 213/790 (27%). POSI-risk with ioMRI showed non-significant unadjusted OR (95% CI) 0.83 (0.53;1.30); adjusted OR 0.76 (0.43;1.35). Fewer CNDs were observed with ioMRI (unadjusted OR 0.63 (0.40;1.00), adjusted OR 0.58 (0.33;0.94), p = 0.03). POSI-risk was associated with more CNDs (adjusted OR for 1 CND: 2.06 (1.15;3.68); 2 CND: 2.13 (1.02;4.42); >= 3 CND: 4.15 (1.98;8.70), p < 0.05). Conclusions ioMRI was not associated with increased risk of postoperative complications in this multicenter cohort. The reduction in CND among ioMRI cases may reflect derived effects on surgical decision-making, expertise, case-load and case-mix. Results should be interpreted with caution due to limited intraoperative data. The association between POSI-risk and cumulative CND may indicate extensive brainstem involvement. Our findings highlight the need to further explore how ioMRI-guided strategies affect functional outcomes in pediatric PF tumour surgery.},
	keywords = {MAGNETIC-RESONANCE; RESECTION; mutism; Pediatric neurosurgery; Clinical Neurology; intraoperative magnetic resonance imaging; posterior fossa tumor; cerebellar mutism syndrome; cranial nerve deficits},
	year = {2025},
	eissn = {0942-0940},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:36366328,
	title = {Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma : Data from the Hungarian Pediatric Oncology Network},
	url = {https://m2.mtmt.hu/api/publication/36366328},
	author = {Hernádfői, Márk Viktor and Szabados, Márton and Brückner, Edit and Varga, Ágnes and Hauser, Péter and Ottóffy, Gábor and Vojcek, Ágnes and Csanádi, Krisztina and Kertész, Gabriella and Jakab, Zsuzsanna and Agócs, Gergely and Garami, Miklós},
	doi = {10.3390/jcm14186641},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {14},
	unique-id = {36366328},
	abstract = {Background/Objectives: The anti-GD2 monoclonal antibody dinutuximab beta has become standard of care maintenance therapy for high-risk neuroblastoma (HR-NB) in the first-line setting and is also approved in the relapsed/refractory setting. We present a retrospective review of 37 children with HR-NB included in the Hungarian Childhood Cancer Registry who received dinutuximab beta (first-line maintenance therapy, n = 31; relapsed/refractory, n = 6). Methods: All patients received dinutuximab beta continuously over the first 10 days of each 35-day cycle, with dosing based on body surface area/weight. Five cycles were planned, with further cycles administered at the treating physician's discretion. Results: At data cutoff, the overall disease control rate was 54.1% (20/37) (complete response, 51.4% (19/37); partial response, 0.0% (0/37), stable disease, 2.7% [1/37]); two patients (5.4%) had progressive disease, and 15 patients (40.5%) had died. The 5-year overall survival (OS) and event-free survival (EFS) rates in the overall population were 63.3% (95% confidence interval, 49.1-81.7) and 56.2% (95% confidence interval, 42.1-75.0), respectively. Grade 3 or 4 adverse events (including blood and lymphatic system disorders, hypoxia, hypotension, and capillary leak syndrome) were generally consistent with dinutuximab beta's known safety profile. Conclusions: Dinutuximab beta was an effective immunotherapy for patients with HR-NB in routine clinical practice, with a generally manageable side effect profile.},
	keywords = {immunotherapy; maintenance therapy; high-risk neuroblastoma; dinutuximab beta; anti-GD2 monoclonal antibody; refractory and relapsed neuroblastoma},
	year = {2025},
	eissn = {2077-0383},
	orcid-numbers = {Brückner, Edit/0000-0002-2140-3357; Hauser, Péter/0000-0002-8307-8975; Csanádi, Krisztina/0009-0001-6277-0137; Jakab, Zsuzsanna/0000-0002-5410-1187; Agócs, Gergely/0000-0003-2489-3790; Garami, Miklós/0000-0003-4298-2746}
}

@{MTMT:34200801,
	title = {A központi idegrendszer daganatai},
	url = {https://m2.mtmt.hu/api/publication/34200801},
	author = {Hauser, Péter and Garami, Miklós},
	booktitle = {Klinikai gyermekgyógyászat},
	unique-id = {34200801},
	year = {2024},
	pages = {787-788},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975; Garami, Miklós/0000-0003-4298-2746}
}

@{MTMT:34200803,
	title = {Gliomák},
	url = {https://m2.mtmt.hu/api/publication/34200803},
	author = {Hauser, Péter and Garami, Miklós},
	booktitle = {Klinikai gyermekgyógyászat},
	unique-id = {34200803},
	year = {2024},
	pages = {788-790},
	orcid-numbers = {Hauser, Péter/0000-0002-8307-8975; Garami, Miklós/0000-0003-4298-2746}
}